These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 12419098)

  • 21. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.
    Torkildsen GL; Williams JI; Gow JA; Gomes PJ; Abelson MB; McNamara TR;
    Ann Allergy Asthma Immunol; 2010 Jul; 105(1):57-64. PubMed ID: 20642205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
    Spangler DL; Bensch G; Berdy GJ
    Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
    Deschenes J; Discepola M; Abelson M
    Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA; Leahy C; Krenzer KL
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
    Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
    Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB; Lanier RQ
    Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
    Abelson MB
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model.
    D'Arienzo PA; Leonardi A; Bensch G
    Clin Ther; 2002 Mar; 24(3):409-16. PubMed ID: 11952024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemirolast, a new oral nonbronchodilator drug for chronic asthma.
    Kemp JP; Bernstein IL; Bierman CW; Li JT; Siegel SC; Spangenberg RD; Tinkelman DG
    Ann Allergy; 1992 Jun; 68(6):488-91. PubMed ID: 1610024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
    Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
    Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A; Abelson MB
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
    Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ
    Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.
    Abelson MB; Chapin MJ; Kapik BM; Shams NB
    Arch Ophthalmol; 2003 May; 121(5):626-30. PubMed ID: 12742839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
    Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
    Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nedocromil sodium 2% ophthalmic solution for the treatment of ragweed pollen seasonal allergic conjunctivitis.
    Blumenthal MN; Schwartz RH; Kaiser H
    Ocul Immunol Inflamm; 2000 Sep; 8(3):159-67. PubMed ID: 11120577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.